← Eichor
Condition: Metastatic Neuroendocrine Prostate Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Metastatic Neuroendocrine Prostate Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Can
Phase 2 · 13 location(s) · National Cancer Institute (NCI) · NCT05691465Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) a
Phase 2 · 1 location(s) · Tianjin Medical University Second Hospital · NCT07179783SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
Phase 1 · 20 location(s) · SystImmune Inc. · NCT07080242Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
Phase 1 · 2 location(s) · Brigham and Women's Hospital · NCT06062745Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME T
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT04693377Cancer Experience Registry (CER) for Cancer Patients and Caregivers
Phase N/A · 1 location(s) · Cancer Support Community, Research and Training Institute, P · NCT02333604Clinical Application of the J-PET Scanner Prototype
Phase N/A · 1 location(s) · Jagiellonian University · NCT06242119Ivonescimab in the Treatment of Multiple Advanced Tumors
Phase 2 · 1 location(s) · Fudan University · NCT06683846A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Phase 1/Phase 2 · 107 location(s) · DualityBio Inc. · NCT05914116Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494SL-28 for Advanced Solid Tumours
Phase 1/Phase 2 · 1 location(s) · Second Life Therapeutics · NCT07341737Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers
NA · 1 location(s) · Institut Claudius Regaud · NCT06967961A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 2 · 85 location(s) · Daiichi Sankyo · NCT06172478Pharmaceutical Management in Targeted Radioligand Therapy
Phase N/A · 3 location(s) · Hospices Civils de Lyon · NCT07389512Integrated Cancer Repository for Cancer Research
Phase N/A · 42 location(s) · University of Nebraska · NCT02012699EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410676Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabo
Phase 2 · 582 location(s) · National Cancer Institute (NCI) · NCT03866382Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms
Phase 1/Phase 2 · 1 location(s) · Vector Vitale LLC · NCT06506643TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Phase 1 · 41 location(s) · Tizona Therapeutics, Inc · NCT04485013IDOV-Immune for Advanced Solid Tumors
Phase 1 · 5 location(s) · ViroMissile, Inc. · NCT06910657
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.